Analysis cut-off date: September 30, 2015.
CHECKMATE 026:
Nivolumab
Histology
1
0 . 5
2
4
1
0 . 5
2
4
Subgroup
Patients, n
Unstratified HR
Unstratified HR (95% CI)
Nivolumab Chemotherapy PFS
OS PFS
OS
Overall
271
270
1.19
1.08
≥65 years
123
137
1.21
1.04
<65 years
148
133
1.17
1.13
Male
184
148
1.05
0.97
Female
87
122
1.36
1.15
ECOG PS = 0
85
93
1.69
1.11
ECOG PS ≥1
185
177
1.01
1.02
Squamous
65
64
0.83
0.82
Non-squamous
206
206
1.29
1.17
Never smoker
30
29
2.51
1.02
Former smoker
186
182
1.14
1.09
Current smoker
52
55
1.03
1.05
≥50% PD-L1+
88
126
1.07
0.90
PFS and OS Subgroup Analyses (All Randomized Patients)
CheckMate 026: Nivolumab vs Chemotherapy in First-line NSCLC
18
Nivolumab
Chemotherapy
Nivolumab
Chemotherapy
Socinski M A et al ESMO 2016
